secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001104659-22-059435
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Q1 continuing ops loss $8.7M; divested MST franchise for $25M; positive FMX114 Phase 1b data
--------------------------------------------------------------------------------

- Q1 2022 GAAP loss from continuing ops $8.7M ($7.4M adjusted); net income $4.7M reflecting divestiture gain.
- Divested MST franchise (AMZEEQ, ZILXI) to Journey Medical for $25M upfront plus up to $450M milestones.
- FMX114 Phase 1b showed stat sig reduction in ADSI score vs vehicle; Phase 2a topline expected Q2 2022.
- VYN201 preclinical data demonstrated efficacy in rheumatoid arthritis and vitiligo models vs active controls.
- Entered $30M equity purchase agreement with Lincoln Park Capital over 36 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922059435/0001104659-22-059435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922059435/tm2215162d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-059435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer